<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554070</url>
  </required_header>
  <id_info>
    <org_study_id>Sechenov-ThuFLEP18</org_study_id>
    <nct_id>NCT03554070</nct_id>
  </id_info>
  <brief_title>Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP): Efficacy and Safety</brief_title>
  <official_title>Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP): Short-Term Efficacy and Safety Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to estimate the efficacy, safety and postoperative complications of
      the thulium fiber laser enucleation of the prostate (ThuFLEP) with Urolase system (NTO
      IRE-POLUS, Russia).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In all patients, IPSS, Qmax, QoL, prostate volume, and IIEF-5 are measured prior to surgery.

      For ThuFLEP, we use the Urolase system (NTO IRE-POLUS, Russia) and a 600 mcm fiber. The
      thulium fiber laser is set with a mean output power of 60 W and energy of 1.5 J. Tissue
      morcellation is completed with the Piranha Morcellator (Richard Wolf, Germany).

      At the end of the procedure a 22 French three-way Foley catheter is placed. IPSS, Qmax, QoL,
      prostate volume are recorded at 1, 3 and 6 months after surgery. IIEF-5 are recorded at 3 and
      6 months after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline IPSS at 1,3 and 6 months</measure>
    <time_frame>baseline and at 1,3 and 6 months</time_frame>
    <description>International Prostate Symptom Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Qmax at 1,3 and 6 months</measure>
    <time_frame>baseline and at 1,3 and 6 months</time_frame>
    <description>Maximal urinary flow rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline QoL at 1,3 and 6 months</measure>
    <time_frame>baseline and at 1,3 and 6 months</time_frame>
    <description>Quality of Life (IPSS-QoL scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline IIEF-5 at 3 and 6 months</measure>
    <time_frame>baseline and at 3 and 6 months</time_frame>
    <description>The International Index of Erectile Function - 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Prostate Volume at 1,3 and 6 months</measure>
    <time_frame>baseline and at 1,3 and 6 months</time_frame>
    <description>Prostate volume measured by ultrasound (transrectal or abdominal)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Infravesical Obstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with infravesical obstruction due to BPH (IPSS &gt; 20, Qmax &lt; 10), who underwent Thulium Fiber Laser Enucleation of the Prostate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thulium Fiber Laser Enucleation of the Prostate</intervention_name>
    <description>Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.</description>
    <arm_group_label>Infravesical Obstruction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thulium Fiber Laser &quot;Urolase&quot;</intervention_name>
    <description>Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.
Max. power of 120 W and energy of 8 J. Wavelength - 1,94 Âµm, incision depth - 0,2 mm.</description>
    <arm_group_label>Infravesical Obstruction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 18 or older

          -  Infravesical obstruction due to prostatic hyperplasia (IPSS &gt; 20 or Qmax &lt;10)

        Exclusion Criteria:

          -  Participation in another clinical study

          -  Prostate cancer (pathology confirmed)

          -  Urinary tract infection

          -  Neurogenic bladder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitry Enikeev</last_name>
    <role>Study Director</role>
    <affiliation>I.M. Sechenov First Moscow State Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of Urology, I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Enikeev D, Glybochko P, Okhunov Z, Alyaev Y, Rapoport L, Tsarichenko D, Enikeev M, Sorokin N, Dymov A, Taratkin M. Retrospective Analysis of Short-Term Outcomes After Monopolar Versus Laser Endoscopic Enucleation of the Prostate: A Single Center Experience. J Endourol. 2018 May;32(5):417-423. doi: 10.1089/end.2017.0898. Epub 2018 Mar 13.</citation>
    <PMID>29430969</PMID>
  </reference>
  <reference>
    <citation>Glybochko PV, Rapoport LM, Enikeev ME, Enikeev DV. Holmium laser enucleation of the prostate (HoLEP) for small, large and giant prostatic hyperplasia: tips and tricks. Urologia. 2017 Aug 1;84(3):169-173. doi: 10.5301/uj.5000232. Epub 2017 May 10.</citation>
    <PMID>28497447</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Dmitry Enikeev, MD, PhD</investigator_full_name>
    <investigator_title>Deputy Director for Science</investigator_title>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>BPH</keyword>
  <keyword>Laser</keyword>
  <keyword>Endoscopic Enucleation of the Prostate</keyword>
  <keyword>Thulium</keyword>
  <keyword>Thulium Fiber Laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

